Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) is expected to post its quarterly earnings results before the market opens on Thursday, May 8th. Analysts expect Oramed Pharmaceuticals to post earnings of ($0.03) per share for the quarter.
Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last released its earnings results on Thursday, March 27th. The biotechnology company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.04. On average, analysts expect Oramed Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Oramed Pharmaceuticals Trading Down 0.9 %
Shares of Oramed Pharmaceuticals stock traded down $0.02 on Tuesday, hitting $2.29. 12,961 shares of the company traded hands, compared to its average volume of 153,991. The company has a market cap of $93.55 million, a PE ratio of 20.82 and a beta of 1.65. The stock's 50 day moving average price is $2.26 and its 200-day moving average price is $2.31. Oramed Pharmaceuticals has a 52 week low of $1.82 and a 52 week high of $3.09.
Analyst Ratings Changes
Separately, StockNews.com upgraded Oramed Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday, May 1st.
Check Out Our Latest Research Report on ORMP
About Oramed Pharmaceuticals
(
Get Free Report)
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.
Featured Stories
Before you consider Oramed Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oramed Pharmaceuticals wasn't on the list.
While Oramed Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
